Cargando…

Clinical applicability of molecular biology: the case of the long QT syndrome

The clinical applicability of molecular cardiology has been questioned at length and by many clinical investigators. The congenital long QT syndrome (LQTS) provides an excellent example of how tight the relationship can be between molecular biology and clinical cardiology. The advent of molecular di...

Descripción completa

Detalles Bibliográficos
Autor principal: Schwartz, Peter J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59606/
https://www.ncbi.nlm.nih.gov/pubmed/11714417
http://dx.doi.org/10.1186/cvm-1-2-088
_version_ 1782120083768737792
author Schwartz, Peter J
author_facet Schwartz, Peter J
author_sort Schwartz, Peter J
collection PubMed
description The clinical applicability of molecular cardiology has been questioned at length and by many clinical investigators. The congenital long QT syndrome (LQTS) provides an excellent example of how tight the relationship can be between molecular biology and clinical cardiology. The advent of molecular diagnosis has demonstrated how low the penetrance can be in LQTS; this implies that there are many gene carriers who do not show the clinical phenotype and may have a normal QT interval despite being at risk. There is also a gene-specific predisposition to be at risk for cardiac arrest under different circumstances, and this provides additional basis for a gene-specific approach to therapy.
format Text
id pubmed-59606
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-596062001-11-06 Clinical applicability of molecular biology: the case of the long QT syndrome Schwartz, Peter J Curr Control Trials Cardiovasc Med Commentary The clinical applicability of molecular cardiology has been questioned at length and by many clinical investigators. The congenital long QT syndrome (LQTS) provides an excellent example of how tight the relationship can be between molecular biology and clinical cardiology. The advent of molecular diagnosis has demonstrated how low the penetrance can be in LQTS; this implies that there are many gene carriers who do not show the clinical phenotype and may have a normal QT interval despite being at risk. There is also a gene-specific predisposition to be at risk for cardiac arrest under different circumstances, and this provides additional basis for a gene-specific approach to therapy. BioMed Central 2000 2000-10-11 /pmc/articles/PMC59606/ /pubmed/11714417 http://dx.doi.org/10.1186/cvm-1-2-088 Text en Copyright © 2000 Current Controlled Trials Ltd
spellingShingle Commentary
Schwartz, Peter J
Clinical applicability of molecular biology: the case of the long QT syndrome
title Clinical applicability of molecular biology: the case of the long QT syndrome
title_full Clinical applicability of molecular biology: the case of the long QT syndrome
title_fullStr Clinical applicability of molecular biology: the case of the long QT syndrome
title_full_unstemmed Clinical applicability of molecular biology: the case of the long QT syndrome
title_short Clinical applicability of molecular biology: the case of the long QT syndrome
title_sort clinical applicability of molecular biology: the case of the long qt syndrome
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59606/
https://www.ncbi.nlm.nih.gov/pubmed/11714417
http://dx.doi.org/10.1186/cvm-1-2-088
work_keys_str_mv AT schwartzpeterj clinicalapplicabilityofmolecularbiologythecaseofthelongqtsyndrome